OneCell Diagnostics Secures $16 Mn Series A Funding to Advance Cancer Diagnostics

OneCell’s flagship product, OncoIndx Alfa, is a next-generation liquid biopsy test designed to detect circulating tumor cells.

OneCell Diagnostics, an artificial intelligence-powered cancer diagnostics startup,has raised $16 million in an oversubscribed Series A funding round.

The investment was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.

The India and Silicon Valley-based company specializes in precision oncology liquid biopsy diagnostics and plans to use the funds to expand access to actionable and affordable cancer diagnostic solutions.

OneCell’s flagship product, OncoIndx Alfa, is a next-generation liquid biopsy test designed to detect circulating tumor cells.

These cells provide critical biomarkers for precision diagnostics, enabling applications such as monitoring treatment response, tracking disease progression, and identifying recurrence.

The technology offers a transformative approach to advancing personalized cancer care.

The funding will support OneCell’s expansion into the U.S. market, allowing broader deployment of OncoIndx Alfa. To date, the company has tested its cell biopsy technology in nearly 10,000 patients in India.

"We envision a future where high-quality, life-saving cancer testing is accessible to all," said Mohan Uttarwar, co-founder and CEO of OneCell Diagnostics.

"By integrating single-cell multi-omics analytics with liquid biopsy, we aim to deliver accurate, personalized cancer care globally."

OneCell’s Strategic Collaborations

As part of the funding, Michael Marks, Celesta Capital’s Founding Managing Partner, and James Rothman, Nobel Laureate, and Celesta Capital Senior Advisor, will join OneCell’s Board of Directors.

Marks highlighted the company’s strategic positioning at the intersection of high-tech and biomedical science, leveraging the US-India corridor for competitive advantages.

"OneCell fits our vision for transformative companies that bridge technology and biomedical innovation," Marks stated. "We are committed to supporting their growth through our extensive ecosystem."

Rothman emphasized the groundbreaking potential of OneCell’s diagnostics in reshaping oncology care.

"Cell biopsy represents a pivotal shift in diagnostics, creating opportunities for highly individualized treatment. We are eager to support OneCell in reaching one million patients and over 1,000 oncologists in the near future," he added.

OneCell collaborates with prominent academic and medical institutions, including AIIMS New Delhi, Tata Memorial Centre, Harvard Medical School, and Stanford University.

These partnerships underline its commitment to advancing cancer diagnostics through cutting-edge research and innovation.

Founded in 2021, OneCell leverages proprietary technology that combines next-generation sequencing, robust bioinformatics, AI/ML, and data analytics for multi-omics biomarkers.

The company’s mission to democratize precision oncology has positioned it as a trailblazer in cancer diagnostics, with its technology poised to redefine global standards in oncology care.

Stay tuned for more such updates on Digital Health News.